SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial

Published: 8 September 2022| Version 1 | DOI: 10.17632/vcfxdvhfw3.1
Contributor:
Bruce Strober

Description

Supplementary materials for the publication of Strober B. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol 2022.

Files

Categories

Clinical Trial, Skin Disease, Psoriasis

License